Indalpine

Identification

Name
Indalpine
Accession Number
DB08953
Type
Small Molecule
Groups
Investigational, Withdrawn
Description

Indalpine was one of the first selective serotonin reuptake inhibitors to reach the American market. It was initially marketed by Pharmuka. However, after the emergence of widespread concern regarding adverse effects caused by SSRIs, and reported hematological effects caused by Indalpine, it was abruptly withdrawn from the US market.

Structure
Thumb
Synonyms
Not Available
External IDs
LM-5008
International/Other Brands
Upstène (Pharmuka)
Categories
UNII
V35562QSVT
CAS number
63758-79-2
Weight
Average: 228.3327
Monoisotopic: 228.16264865
Chemical Formula
C15H20N2
InChI Key
SADQVAVFGNTEOD-UHFFFAOYSA-N
InChI
InChI=1S/C15H20N2/c1-2-4-15-14(3-1)13(11-17-15)6-5-12-7-9-16-10-8-12/h1-4,11-12,16-17H,5-10H2
IUPAC Name
3-[2-(piperidin-4-yl)ethyl]-1H-indole
SMILES
C(CC1=CNC2=CC=CC=C12)C1CCNCC1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Indalpine.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Indalpine.Experimental
AcarboseIndalpine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Indalpine.Approved, Investigational
AceclofenacIndalpine may increase the antiplatelet activities of Aceclofenac.Approved, Investigational
AcenocoumarolIndalpine may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Indalpine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Indalpine.Approved
Acetylsalicylic acidIndalpine may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Indalpine.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Indalpine.Approved, Investigational
AlaproclateIndalpine may increase the serotonergic activities of Alaproclate.Experimental
AlbiglutideIndalpine may increase the hypoglycemic activities of Albiglutide.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Indalpine.Vet Approved
AlfentanilAlfentanil may increase the serotonergic activities of Indalpine.Approved, Illicit
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Indalpine.Approved, Vet Approved
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Indalpine.Investigational
AlogliptinIndalpine may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Indalpine.Experimental, Illicit
AlphaprodineAlphaprodine may increase the serotonergic activities of Indalpine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Indalpine.Approved, Illicit, Investigational
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Indalpine.Approved, Withdrawn
AmikacinThe risk or severity of adverse effects can be increased when Amikacin is combined with Indalpine.Approved, Investigational, Vet Approved
Aminosalicylic AcidIndalpine may increase the antiplatelet activities of Aminosalicylic Acid.Approved
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Indalpine.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Indalpine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Indalpine.Approved, Illicit
AmoxapineIndalpine may increase the serotonergic activities of Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Indalpine.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Indalpine is combined with Amphetamine.Approved, Illicit, Investigational
AntipyrineIndalpine may increase the antiplatelet activities of Antipyrine.Approved, Investigational
AntrafenineIndalpine may increase the antiplatelet activities of Antrafenine.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Indalpine.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Indalpine.Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Indalpine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Indalpine.Approved
AtenololThe serum concentration of Atenolol can be increased when it is combined with Indalpine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Indalpine.Investigational, Vet Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Indalpine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Indalpine.Approved
BalsalazideIndalpine may increase the antiplatelet activities of Balsalazide.Approved, Investigational
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Indalpine.Illicit
BefunololThe serum concentration of Befunolol can be increased when it is combined with Indalpine.Experimental
BendroflumethiazideIndalpine may increase the hyponatremic activities of Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Indalpine is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Indalpine.Approved, Investigational
BenzphetamineThe risk or severity of serotonin syndrome can be increased when Indalpine is combined with Benzphetamine.Approved, Illicit
BenzthiazideIndalpine may increase the hyponatremic activities of Benzthiazide.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Indalpine.Approved
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Indalpine.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Indalpine.Approved, Investigational
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Indalpine.Approved
BezitramideBezitramide may increase the serotonergic activities of Indalpine.Experimental, Illicit, Withdrawn
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Indalpine.Approved
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Indalpine.Investigational
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Indalpine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Indalpine.Approved, Investigational
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Indalpine.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Indalpine is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Indalpine.Approved, Illicit, Investigational
BromfenacIndalpine may increase the antiplatelet activities of Bromfenac.Approved
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Indalpine.Experimental
BromocriptineIndalpine may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Indalpine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Indalpine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Indalpine.Approved, Investigational, Withdrawn
BucindololThe serum concentration of Bucindolol can be increased when it is combined with Indalpine.Investigational
BufexamacIndalpine may increase the antiplatelet activities of Bufexamac.Approved, Experimental
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Indalpine.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Indalpine.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Indalpine.Approved
BuprenorphineBuprenorphine may increase the serotonergic activities of Indalpine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Indalpine.Approved
BuspironeBuspirone may increase the serotonergic activities of Indalpine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Indalpine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Indalpine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Indalpine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Indalpine.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Indalpine.Approved, Illicit
ButorphanolButorphanol may increase the serotonergic activities of Indalpine.Approved, Illicit, Vet Approved
CanagliflozinIndalpine may increase the hypoglycemic activities of Canagliflozin.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Indalpine.Investigational
CapsaicinIndalpine may increase the antiplatelet activities of Capsaicin.Approved
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Indalpine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Indalpine.Approved
CarfentanilCarfentanil may increase the serotonergic activities of Indalpine.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Indalpine.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Indalpine is combined with Caroxazone.Withdrawn
CarprofenIndalpine may increase the antiplatelet activities of Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe serum concentration of Carteolol can be increased when it is combined with Indalpine.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Indalpine.Approved, Investigational
CelecoxibIndalpine may increase the antiplatelet activities of Celecoxib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Indalpine.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Indalpine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Indalpine.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Indalpine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Indalpine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Indalpine.Approved
ChlorothiazideIndalpine may increase the hyponatremic activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Indalpine.Approved
ChlorphenesinIndalpine may increase the antiplatelet activities of Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Chlorproethazine is combined with Indalpine.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Indalpine.Approved, Investigational, Vet Approved
ChlorpropamideIndalpine may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Indalpine.Approved, Investigational, Withdrawn
ChlorthalidoneIndalpine may increase the hyponatremic activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Indalpine.Approved
Choline magnesium trisalicylateIndalpine may increase the antiplatelet activities of Choline magnesium trisalicylate.Approved
CimetidineThe metabolism of Indalpine can be decreased when combined with Cimetidine.Approved, Investigational
CimicoxibIndalpine may increase the antiplatelet activities of Cimicoxib.Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Indalpine.Approved, Vet Approved
CisplatinIndalpine may increase the antiplatelet activities of Cisplatin.Approved
CitalopramIndalpine may increase the serotonergic activities of Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Indalpine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Indalpine.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Indalpine.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Indalpine.Approved, Illicit
Clodronic AcidIndalpine may increase the antiplatelet activities of Clodronic Acid.Approved, Investigational, Vet Approved
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Indalpine.Investigational
ClomipramineIndalpine may increase the serotonergic activities of Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Indalpine.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Indalpine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Indalpine.Experimental
CloranololThe serum concentration of Cloranolol can be increased when it is combined with Indalpine.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Indalpine.Approved, Illicit
ClorindioneIndalpine may increase the anticoagulant activities of Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Indalpine.Experimental
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Indalpine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Indalpine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Indalpine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Indalpine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Indalpine is combined with Cyclobenzaprine.Approved
CyclopenthiazideIndalpine may increase the hyponatremic activities of Cyclopenthiazide.Experimental
CyclopropaneThe risk or severity of adverse effects can be increased when Cyclopropane is combined with Indalpine.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Indalpine.Approved, Investigational, Vet Approved
CyproheptadineThe therapeutic efficacy of Indalpine can be decreased when used in combination with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Indalpine.Approved, Investigational
DapagliflozinIndalpine may increase the hypoglycemic activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Indalpine.Approved
DapoxetineDapoxetine may increase the serotonergic activities of Indalpine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Indalpine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Indalpine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Indalpine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Indalpine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Indalpine is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Indalpine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Indalpine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Indalpine.Approved
DexibuprofenIndalpine may increase the antiplatelet activities of Dexibuprofen.Approved, Investigational
DexketoprofenIndalpine may increase the antiplatelet activities of Dexketoprofen.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Indalpine.Approved, Vet Approved
DextromethorphanIndalpine may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideDextromoramide may increase the serotonergic activities of Indalpine.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Indalpine.Approved, Illicit, Investigational, Withdrawn
DezocineDezocine may increase the serotonergic activities of Indalpine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Indalpine.Approved, Illicit, Investigational, Vet Approved
DiclofenacIndalpine may increase the antiplatelet activities of Diclofenac.Approved, Vet Approved
DicoumarolIndalpine may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Indalpine.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Indalpine.Approved, Illicit
DiflunisalIndalpine may increase the antiplatelet activities of Diflunisal.Approved, Investigational
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Indalpine.Approved, Illicit
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Indalpine.Experimental, Illicit
DihydromorphineDihydromorphine may increase the serotonergic activities of Indalpine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Indalpine.Approved
DiphenadioneIndalpine may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Indalpine.Approved, Investigational
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Indalpine.Approved, Illicit
DisopyramideIndalpine may increase the hypoglycemic activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Indalpine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Indalpine.Vet Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Indalpine.Approved
DotarizineThe risk or severity of adverse effects can be increased when Dotarizine is combined with Indalpine.Investigational
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Indalpine.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Indalpine.Approved, Vet Approved
DPDPEDPDPE may increase the serotonergic activities of Indalpine.Experimental
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Indalpine.Approved, Vet Approved
DrospirenoneIndalpine may increase the antiplatelet activities of Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Indalpine.Experimental, Illicit
DroxicamIndalpine may increase the antiplatelet activities of Droxicam.Withdrawn
DulaglutideIndalpine may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuloxetineDuloxetine may increase the serotonergic activities of Indalpine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Indalpine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Indalpine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Indalpine.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Indalpine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Indalpine.Investigational
EmpagliflozinIndalpine may increase the hypoglycemic activities of Empagliflozin.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Indalpine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Indalpine.Approved, Investigational
EpanololThe serum concentration of Epanolol can be increased when it is combined with Indalpine.Experimental
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Indalpine.Approved, Investigational
EpitizideIndalpine may increase the hyponatremic activities of Epitizide.Experimental
EsatenololThe serum concentration of Esatenolol can be increased when it is combined with Indalpine.Experimental
EscitalopramIndalpine may increase the serotonergic activities of Escitalopram.Approved, Investigational
EsmololThe serum concentration of Esmolol can be increased when it is combined with Indalpine.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Indalpine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Indalpine.Approved, Investigational
EtanerceptIndalpine may increase the antiplatelet activities of Etanercept.Approved, Investigational
EthanolIndalpine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Indalpine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Indalpine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Indalpine.Approved
Ethyl biscoumacetateIndalpine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Indalpine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Indalpine.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Indalpine.Approved, Illicit
EthylmorphineEthylmorphine may increase the serotonergic activities of Indalpine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Indalpine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Indalpine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Indalpine.Approved
EtodolacIndalpine may increase the antiplatelet activities of Etodolac.Approved, Investigational, Vet Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Indalpine.Approved
EtoperidoneEtoperidone may increase the serotonergic activities of Indalpine.Withdrawn
EtoricoxibIndalpine may increase the antiplatelet activities of Etoricoxib.Approved, Investigational
EtorphineEtorphine may increase the serotonergic activities of Indalpine.Illicit, Vet Approved
ExenatideIndalpine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Indalpine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Indalpine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Indalpine.Approved, Illicit, Withdrawn
FenfluramineIndalpine may increase the serotonergic activities of Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenoprofenIndalpine may increase the antiplatelet activities of Fenoprofen.Approved
FentanylThe risk or severity of serotonin syndrome can be increased when Fentanyl is combined with Indalpine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Indalpine.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Indalpine.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Indalpine.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Indalpine.Approved, Illicit
FluindioneIndalpine may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Indalpine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Indalpine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Indalpine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Indalpine.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Indalpine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Indalpine.Approved, Illicit, Investigational
FlurbiprofenIndalpine may increase the antiplatelet activities of Flurbiprofen.Approved, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Indalpine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Indalpine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Indalpine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Indalpine.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Indalpine.Approved, Illicit, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Indalpine.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Indalpine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Indalpine.Approved, Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Indalpine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Indalpine.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Indalpine.Investigational
GinsengIndalpine may increase the antiplatelet activities of Ginseng.Approved, Investigational, Nutraceutical
GliclazideIndalpine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideIndalpine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideIndalpine may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Indalpine.Approved, Illicit
GlyburideIndalpine may increase the hypoglycemic activities of Glyburide.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Indalpine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Indalpine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Indalpine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Indalpine.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Indalpine is combined with Harmaline.Experimental
HeroinHeroin may increase the serotonergic activities of Indalpine.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Indalpine.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Indalpine is combined with Hydracarbazine.Experimental
HydrochlorothiazideThe risk or severity of hyponatremia can be increased when Indalpine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneIndalpine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideIndalpine may increase the hyponatremic activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneHydromorphone may increase the serotonergic activities of Indalpine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Indalpine.Approved
IcosapentIndalpine may increase the antiplatelet activities of Icosapent.Approved, Nutraceutical
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Indalpine.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Indalpine.Approved
IndapamideIndalpine may increase the hyponatremic activities of Indapamide.Approved
IndenololThe serum concentration of Indenolol can be increased when it is combined with Indalpine.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Indalpine.Investigational
IndomethacinIndalpine may increase the antiplatelet activities of Indomethacin.Approved, Investigational
Insulin AspartIndalpine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirIndalpine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineIndalpine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineIndalpine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanIndalpine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproIndalpine may increase the hypoglycemic activities of Insulin Lispro.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Indalpine.Approved, Investigational
Ioflupane I-123Indalpine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IproclozideThe risk or severity of adverse effects can be increased when Indalpine is combined with Iproclozide.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Indalpine.Withdrawn
IsocarboxazidThe therapeutic efficacy of Indalpine can be increased when used in combination with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Indalpine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Indalpine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Indalpine.Approved
KetobemidoneKetobemidone may increase the serotonergic activities of Indalpine.Approved, Investigational
KetoprofenIndalpine may increase the antiplatelet activities of Ketoprofen.Approved, Vet Approved
KetorolacIndalpine may increase the antiplatelet activities of Ketorolac.Approved
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Indalpine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Indalpine.Approved, Investigational
LandiololThe serum concentration of Landiolol can be increased when it is combined with Indalpine.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Indalpine.Approved, Investigational
LevobetaxololThe serum concentration of Levobetaxolol can be increased when it is combined with Indalpine.Approved, Investigational
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Indalpine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Indalpine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Indalpine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Indalpine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Indalpine.Approved
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Indalpine.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the serotonergic activities of Indalpine.Approved, Investigational
LevorphanolLevorphanol may increase the serotonergic activities of Indalpine.Approved
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Indalpine.Approved
LinezolidLinezolid may increase the serotonergic activities of Indalpine.Approved, Investigational
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Indalpine.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Indalpine.Approved
LiraglutideIndalpine may increase the hypoglycemic activities of Liraglutide.Approved
Lithium cationLithium may increase the serotonergic activities of Indalpine.Experimental
LofentanilLofentanil may increase the serotonergic activities of Indalpine.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Indalpine.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Indalpine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Indalpine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Indalpine.Approved
LornoxicamIndalpine may increase the antiplatelet activities of Lornoxicam.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Indalpine.Approved
LumiracoxibIndalpine may increase the antiplatelet activities of Lumiracoxib.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Indalpine.Approved, Investigational
Magnesium carbonateThe risk or severity of adverse effects can be increased when Magnesium carbonate is combined with Indalpine.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Magnesium citrate is combined with Indalpine.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Indalpine.Approved, Investigational
Magnesium salicylateIndalpine may increase the antiplatelet activities of Magnesium salicylate.Approved
Magnesium sulfateThe therapeutic efficacy of Indalpine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Indalpine.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Indalpine.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Indalpine is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Indalpine.Experimental
MecaserminIndalpine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Indalpine.Approved
Meclofenamic acidIndalpine may increase the antiplatelet activities of Meclofenamic acid.Approved, Vet Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Indalpine.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Indalpine.Vet Approved
Mefenamic acidIndalpine may increase the antiplatelet activities of Mefenamic acid.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Indalpine.Approved, Nutraceutical, Vet Approved
MeloxicamIndalpine may increase the antiplatelet activities of Meloxicam.Approved, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Indalpine.Approved, Investigational
MepindololThe serum concentration of Mepindolol can be increased when it is combined with Indalpine.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Indalpine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Indalpine.Approved, Illicit
MeptazinolMeptazinol may increase the serotonergic activities of Indalpine.Experimental
MesalazineIndalpine may increase the antiplatelet activities of Mesalazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Indalpine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Indalpine.Approved
MetforminIndalpine may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Indalpine.Approved
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Indalpine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Indalpine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Indalpine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Indalpine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Indalpine.Approved
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Indalpine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Indalpine.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Indalpine.Approved
MethyclothiazideIndalpine may increase the hyponatremic activities of Methyclothiazide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Indalpine.Experimental
Methylene blueIndalpine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Indalpine.Approved
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Indalpine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Indalpine.Approved, Investigational
MetolazoneIndalpine may increase the hyponatremic activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Indalpine.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Indalpine.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Indalpine.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Indalpine.Approved, Illicit
MifepristoneIndalpine may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolIndalpine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranMilnacipran may increase the serotonergic activities of Indalpine.Approved, Investigational
MinaprineMinaprine may increase the serotonergic activities of Indalpine.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Indalpine.Approved
MoclobemideMoclobemide may increase the serotonergic activities of Indalpine.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Indalpine.Approved
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Indalpine.Approved, Investigational, Withdrawn
MorniflumateIndalpine may increase the antiplatelet activities of Morniflumate.Approved
MorphineMorphine may increase the serotonergic activities of Indalpine.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Indalpine.Approved, Investigational
NabumetoneIndalpine may increase the antiplatelet activities of Nabumetone.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Indalpine.Approved
NaftopidilIndalpine may increase the antiplatelet activities of Naftopidil.Investigational
NalbuphineNalbuphine may increase the serotonergic activities of Indalpine.Approved
NaproxenIndalpine may increase the antiplatelet activities of Naproxen.Approved, Vet Approved
NateglinideIndalpine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Indalpine.Approved, Investigational
NefazodoneNefazodone may increase the serotonergic activities of Indalpine.Approved, Withdrawn
NeomycinThe risk or severity of adverse effects can be increased when Neomycin is combined with Indalpine.Approved, Vet Approved
NepafenacIndalpine may increase the antiplatelet activities of Nepafenac.Approved, Investigational
NialamideNialamide may increase the serotonergic activities of Indalpine.Withdrawn
NicomorphineNicomorphine may increase the serotonergic activities of Indalpine.Experimental
Niflumic AcidIndalpine may increase the antiplatelet activities of Niflumic Acid.Approved
NimesulideIndalpine may increase the antiplatelet activities of Nimesulide.Approved, Investigational, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Indalpine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Indalpine.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Nordazepam is combined with Indalpine.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Indalpine.Approved, Investigational
NormethadoneNormethadone may increase the serotonergic activities of Indalpine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Indalpine.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Indalpine is combined with Octamoxin.Withdrawn
OlanzapineIndalpine may increase the serotonergic activities of Olanzapine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Indalpine.Approved
OndansetronThe risk or severity of serotonin syndrome can be increased when Ondansetron is combined with Indalpine.Approved
OpiumOpium may increase the serotonergic activities of Indalpine.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Indalpine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Indalpine.Investigational
OxaprozinIndalpine may increase the antiplatelet activities of Oxaprozin.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Indalpine.Approved
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Indalpine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Indalpine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Indalpine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Indalpine.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Indalpine.Approved
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Indalpine.Approved, Investigational
ParecoxibIndalpine may increase the antiplatelet activities of Parecoxib.Approved
PargylinePargyline may increase the serotonergic activities of Indalpine.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Indalpine.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Indalpine.Approved, Investigational
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Indalpine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Indalpine.Experimental
PentamidineIndalpine may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
PentazocinePentazocine may increase the serotonergic activities of Indalpine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Indalpine.Approved, Investigational, Vet Approved
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Indalpine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Indalpine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Indalpine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Indalpine.Approved
PethidinePethidine may increase the serotonergic activities of Indalpine.Approved
PhenazocinePhenazocine may increase the serotonergic activities of Indalpine.Experimental
PhenelzinePhenelzine may increase the serotonergic activities of Indalpine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Indalpine.Experimental
PhenindioneIndalpine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazineThe risk or severity of adverse effects can be increased when Indalpine is combined with Pheniprazine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Indalpine.Approved, Investigational
PhenoperidinePhenoperidine may increase the serotonergic activities of Indalpine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Indalpine.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Indalpine is combined with Phenoxypropazine.Withdrawn
PhenprocoumonIndalpine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneIndalpine may increase the antiplatelet activities of Phenylbutazone.Approved, Vet Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Indalpine.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Indalpine.Approved
PindololThe serum concentration of Pindolol can be increased when it is combined with Indalpine.Approved, Investigational
PioglitazoneIndalpine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Indalpine.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Indalpine.Approved, Investigational
PiritramidePiritramide may increase the serotonergic activities of Indalpine.Approved, Investigational
PirlindolePirlindole may increase the serotonergic activities of Indalpine.Approved
PiroxicamIndalpine may increase the antiplatelet activities of Piroxicam.Approved, Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Indalpine is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Indalpine.Approved
Platelet Activating FactorThe serum concentration of Platelet Activating Factor can be increased when it is combined with Indalpine.Experimental
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Polymyxin B Sulfate is combined with Indalpine.Approved, Vet Approved
PolythiazideIndalpine may increase the hyponatremic activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Indalpine.Approved
PractololThe serum concentration of Practolol can be increased when it is combined with Indalpine.Approved
PramipexoleIndalpine may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideIndalpine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Indalpine.Approved, Illicit
PregabalinThe therapeutic efficacy of Indalpine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Indalpine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Indalpine.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Indalpine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Indalpine is combined with Procarbazine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Indalpine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Indalpine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Indalpine.Approved, Investigational
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Indalpine.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Indalpine.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Indalpine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Indalpine.Approved, Investigational
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Indalpine.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Indalpine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Indalpine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Indalpine.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Indalpine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Indalpine.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Indalpine.Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Indalpine.Approved
PyrantelThe risk or severity of adverse effects can be increased when Pyrantel is combined with Indalpine.Approved, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Indalpine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Indalpine.Approved
QuinethazoneIndalpine may increase the hyponatremic activities of Quinethazone.Approved
QuinineIndalpine may increase the hypoglycemic activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Indalpine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Indalpine.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Indalpine.Approved, Investigational
RasagilineRasagiline may increase the serotonergic activities of Indalpine.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Indalpine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Indalpine.Approved, Withdrawn
RepaglinideIndalpine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Indalpine.Approved, Investigational
ResveratrolIndalpine may increase the antiplatelet activities of Resveratrol.Approved, Experimental, Investigational
RisperidoneThe metabolism of Risperidone can be decreased when combined with Indalpine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Indalpine.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Indalpine.Approved
RofecoxibIndalpine may increase the antiplatelet activities of Rofecoxib.Approved, Investigational, Withdrawn
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Indalpine.Vet Approved
RopiniroleIndalpine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Indalpine.Approved
RosiglitazoneIndalpine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Indalpine is combined with Safrazine.Withdrawn
Salicylic acidIndalpine may increase the antiplatelet activities of Salicylic acid.Approved, Investigational, Vet Approved
SalsalateIndalpine may increase the antiplatelet activities of Salsalate.Approved
SaxagliptinIndalpine may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Indalpine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Indalpine.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic activities of Indalpine.Approved, Investigational, Vet Approved
SeliciclibIndalpine may increase the antiplatelet activities of Seliciclib.Investigational
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Indalpine.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Indalpine.Approved, Investigational, Withdrawn
SertralineIndalpine may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Indalpine.Approved, Vet Approved
SitagliptinIndalpine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium CitrateIndalpine may increase the antiplatelet activities of Sodium Citrate.Approved, Investigational
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Indalpine.Approved
SotalolThe serum concentration of Sotalol can be increased when it is combined with Indalpine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Indalpine.Approved
SufentanilSufentanil may increase the serotonergic activities of Indalpine.Approved, Investigational
SulfadiazineIndalpine may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleIndalpine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineIndalpine may increase the antiplatelet activities of Sulfasalazine.Approved
SulfisoxazoleIndalpine may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacIndalpine may increase the antiplatelet activities of Sulindac.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Indalpine.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Indalpine.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Indalpine.Approved, Investigational
SunitinibIndalpine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenIndalpine may increase the antiplatelet activities of Suprofen.Approved, Withdrawn
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Indalpine.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Indalpine.Approved, Investigational
TalinololThe serum concentration of Talinolol can be increased when it is combined with Indalpine.Investigational
TalniflumateIndalpine may increase the antiplatelet activities of Talniflumate.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Indalpine.Investigational
TapentadolTapentadol may increase the serotonergic activities of Indalpine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Indalpine.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Indalpine.Approved, Investigational
TenoxicamIndalpine may increase the antiplatelet activities of Tenoxicam.Approved
TerbutalineThe serum concentration of Terbutaline can be increased when it is combined with Indalpine.Approved
TertatololThe serum concentration of Tertatolol can be increased when it is combined with Indalpine.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Indalpine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Indalpine.Approved, Vet Approved
TetracyclineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Indalpine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Indalpine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Indalpine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Indalpine.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Indalpine.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Thiazinam is combined with Indalpine.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Indalpine.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Indalpine.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Indalpine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Indalpine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Indalpine.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Indalpine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Indalpine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Indalpine.Approved, Investigational
Tiaprofenic acidIndalpine may increase the antiplatelet activities of Tiaprofenic acid.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Indalpine.Vet Approved
TilidineTilidine may increase the serotonergic activities of Indalpine.Experimental
TimololThe serum concentration of Timolol can be increased when it is combined with Indalpine.Approved
TioclomarolIndalpine may increase the anticoagulant activities of Tioclomarol.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Indalpine.Approved, Investigational
TolazamideIndalpine may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamideIndalpine may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Indalpine.Approved, Withdrawn
TolmetinIndalpine may increase the antiplatelet activities of Tolmetin.Approved
ToloxatoneToloxatone may increase the serotonergic activities of Indalpine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Indalpine.Approved
TramadolIndalpine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TranilastIndalpine may increase the antiplatelet activities of Tranilast.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Indalpine is combined with Tranylcypromine.Approved, Investigational
TrazodoneIndalpine may increase the serotonergic activities of Trazodone.Approved, Investigational
TriamcinoloneIndalpine may increase the antiplatelet activities of Triamcinolone.Approved, Vet Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Indalpine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Indalpine.Vet Approved
TrichlormethiazideIndalpine may increase the hyponatremic activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Indalpine.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Indalpine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Indalpine.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Indalpine.Approved, Vet Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Trimethadione is combined with Indalpine.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Indalpine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Indalpine.Approved
Trolamine salicylateIndalpine may increase the antiplatelet activities of Trolamine salicylate.Approved
ValdecoxibIndalpine may increase the antiplatelet activities of Valdecoxib.Approved, Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Indalpine.Approved, Investigational
VancomycinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Indalpine.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Indalpine.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Indalpine.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Indalpine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Indalpine.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Indalpine.Approved
VilazodoneIndalpine may increase the serotonergic activities of Vilazodone.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Indalpine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Indalpine.Experimental
VortioxetineIndalpine may increase the serotonergic activities of Vortioxetine.Approved, Investigational
WarfarinIndalpine may increase the anticoagulant activities of Warfarin.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Indalpine.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Indalpine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Indalpine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Indalpine.Approved
ZimelidineIndalpine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Indalpine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Indalpine.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Indalpine.Approved, Investigational
ZolpidemIndalpine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Indalpine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Indalpine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Indalpine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Indalpine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 4,064,255.

General References
  1. Marcin LR, Mattson RJ, Gao Q, Wu D, Molski TF, Mattson GK, Lodge NJ: Synthesis and hSERT activity of homotryptamine analogs. Part 6: [3+2] dipolar cycloaddition of 3-vinylindoles. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1027-30. doi: 10.1016/j.bmcl.2009.12.043. Epub 2009 Dec 16. [PubMed:20034793]
  2. Galbaud du Fort G: [Hematologic toxicity of antidepressive agents]. Encephale. 1988 Jul-Aug;14(4):307-18. [PubMed:3058454]
External Links
PubChem Compound
44668
PubChem Substance
310264918
ChemSpider
40643
BindingDB
50029150
ChEBI
134939
ChEMBL
CHEMBL276520
Wikipedia
Indalpine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)167 U.S. Patent 4,064,255.
Predicted Properties
PropertyValueSource
Water Solubility0.0125 mg/mLALOGPS
logP3.58ALOGPS
logP3.07ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)17.32ChemAxon
pKa (Strongest Basic)10.36ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area27.82 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity71.77 m3·mol-1ChemAxon
Polarizability27.59 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 3-alkylindoles. These are compounds containing an indole moiety that carries an alkyl chain at the 3-position.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Indoles
Direct Parent
3-alkylindoles
Alternative Parents
Aralkylamines / Substituted pyrroles / Piperidines / Benzenoids / Heteroaromatic compounds / Dialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
3-alkylindole / Aralkylamine / Piperidine / Substituted pyrrole / Benzenoid / Pyrrole / Heteroaromatic compound / Secondary aliphatic amine / Secondary amine / Azacycle
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on May 28, 2014 11:04 / Updated on August 02, 2018 06:12